Ocular drug delivery

• US 20050181018A1
• Filed: 04/14/2005
• Published: 08/18/2005
• Est. Priority Date: 09/19/2003
• Status: Abandoned Application

• Current Assignee: Minu, LLC
• Original Assignee: Minu, LLC
• Inventors: Peyman, Gholam A.
• Application Number:
  US11/105,756
• Publication Number:
  US 20050181018A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/7052 having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

An ocular device that contains a drug, the device affixed to the sclera for release of drug into the sclera through at least one opening. Control of drug release may be mechanical and/or electrical, and may be at a point of use or from a remote location. In one embodiment, an electrode is affixed to the sclera opposite the device, and initiation of current releases the drug from the device via iontophoresis. The lumen or reservoir contents may be visualized, and/or an indicator may indicate content information such as volume. In one embodiment, a multicompartment device may controllably release the same drug at a different rate or different drugs at the same or different rates.

Claims

1. A method for ocular drug delivery comprising providing to an eye of a patient a delivery device having at least one opening for release of an agent contained within at least one lumen of the device, and fixing the device to the sclera such that the agent is released into the sclera through the opening.

2. The method of claim 1 wherein the device is fixed to the sclera substantially adjacent the conjunctiva or under the conjunctiva.

3. The method of claim 1 wherein release of agent from the device is regulated remotely.

4. The method of claim 1 wherein an electrically-disruptable material is associated with the opening and an electrical stimulus disrupts the material to release the agent

5. The method of claim 1 wherein the device further comprises at least one electrode and an opposite electrode is fixed to the sclera substantially opposite the device, and a current is generated to provide release of the agent from the device by iontophoresis.

6. The method of claim 1 wherein the agent is selected from the group consisting of an antibiotic, anti-inflammatory, anti-proliferative, hormone, cytokine, growth factor, antibody, immune modulator, vector for gene therapy, oligo, enzyme, enzyme inhibitors, and combinations thereof.

7. The method of claim 1 wherein the lumen is separated into at least a first compartment and a second compartment.

8. The method of claim 7 wherein a drug is contained in each compartment and release of the drug from each compartment is independently controlled.

9. The method of claim 1 wherein the contents of the lumen are detectable in the affixed device.

10. The method of claim 1 wherein the device is affixed to an outer scleral wall.

11. The method of claim 1 wherein the device is affixed by an adhesive, a sealant, or combinations thereof.

12. The method of claim 1 wherein the device is inserted into a tunnel created in the sclera.

13. The method of claim 1 wherein a pre-filled device is inserted.

14. The method of claim 1 wherein the device further comprises a port and the device is refillable through the port.

15. The method of claim 1 wherein the device is encapsulated.

16. The method of claim 1 wherein at least a portion of the device or the agent is in a nanotechnology formulation.

17. An ocular drug delivery device comprising at least one lumen for containing a pharmaceutically active agent, at least one controllable opening, a subtantially linear body, the device shaped for affixing to a sclera in approximation to a conjunctiva or for locating within a tunnel created in a sclera, the device capable of controllably releasing agent contained in the lumen from the opening.

18. The device of claim 17 having at least two lumens.

19. The device of claim 17 further comprising means associated with the opening for control of drug release from a remote location.

20. The device of claim 17 at least a portion of which is nanotechnology.